Noci Darlene 4
4 · Nuvalent, Inc. · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
Nuvalent CDO Darlene Noci Sells 23,000 Shares, Exercises Options
What Happened
- Darlene Noci, Chief Development Officer of Nuvalent, exercised stock options to acquire a total of 23,000 shares (9,146 at $18.93 and 13,854 at $72.35) on July 1, 2026, paying $173,134 and $1,002,337 respectively. On the same day she sold 23,000 shares in an open-market transaction for total proceeds of $2,842,570 (weighted average sale price $123.59).
Key Details
- Transaction date: July 1, 2026.
- Option exercises (acquisitions): 9,146 shares @ $18.93 = $173,134; 13,854 shares @ $72.35 = $1,002,337.
- Open-market sale (disposition): 23,000 shares @ weighted avg $123.59 = $2,842,570 (sale prices ranged $123.51–$123.62).
- The filing also records the corresponding disposition of the derivative instruments at $0.00 (these entries reflect the options being converted/terminated upon exercise).
- Footnotes: transactions effected under a Rule 10b5-1 trading plan adopted Nov 18, 2024 (F1). Sale price reported as weighted average; seller will provide per-price breakdown on request (F2). One option grant is fully vested (F3); the other vests monthly over four years beginning Jan 5, 2024 (F4).
- Shares owned after the transactions: not specified in the provided filing.
Context
- This appears to be a routine cashless-style sequence: options were exercised and the resulting shares were sold the same day under a pre-established 10b5-1 plan. Exercises indicate conversion of derivatives into common stock; the $0.00 derivative disposition lines reflect the option instruments ceasing to exist after exercise.
- The 10b5-1 plan note means the trades were made under a pre-set plan adopted in 2024, which is common for executive trading and reduces concerns about ad-hoc timing.
Insider Transaction Report
Form 4
Nuvalent, Inc.NUVL
Noci Darlene
Chief Development Officer
Transactions
- Exercise/Conversion
Class A Common Stock
[F1]2026-07-01$18.93/sh+9,146$173,134→ 67,263 total - Exercise/Conversion
Class A Common Stock
[F1]2026-07-01$72.35/sh+13,854$1,002,337→ 81,117 total - Sale
Class A Common Stock
[F1][F2]2026-07-01$123.59/sh−23,000$2,842,570→ 58,117 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-07-01−9,146→ 15,112 totalExercise: $18.93Exp: 2032-01-04→ Class A Common Stock (9,146 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]2026-07-01−13,854→ 33,646 totalExercise: $72.35Exp: 2034-01-05→ Class A Common Stock (13,854 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.51 to $123.62, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
- [F3]The shares underlying this option are fully vested.
- [F4]The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
Signature
/s/ Nathan McConarty, attorney-in-fact|2026-07-06